TNFRSF9 and breast carcinoma: In models of renal and breast cancer combination treatment of α-GalCer with agonistic anti-DR5 and anti-41BB antibodies or agonistic anti-CD40 and anti-4-1BB antibodies led to a significant increase in tumor regression compared to monoclonal antibody therapy alone, with 80% of mice having complete tumor regression [120,121].